IL154928A0 - 3-substituted oxindole beta 3 agonists - Google Patents
3-substituted oxindole beta 3 agonistsInfo
- Publication number
- IL154928A0 IL154928A0 IL15492801A IL15492801A IL154928A0 IL 154928 A0 IL154928 A0 IL 154928A0 IL 15492801 A IL15492801 A IL 15492801A IL 15492801 A IL15492801 A IL 15492801A IL 154928 A0 IL154928 A0 IL 154928A0
- Authority
- IL
- Israel
- Prior art keywords
- beta
- agonists
- substituted oxindole
- sub
- oxindole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24730400P | 2000-11-10 | 2000-11-10 | |
| US30679301P | 2001-07-20 | 2001-07-20 | |
| PCT/US2001/050666 WO2002038544A2 (en) | 2000-11-10 | 2001-10-26 | 3-substituted oxindole beta 3 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL154928A0 true IL154928A0 (en) | 2003-10-31 |
Family
ID=26938590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15492801A IL154928A0 (en) | 2000-11-10 | 2001-10-26 | 3-substituted oxindole beta 3 agonists |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6825220B2 (es) |
| EP (1) | EP1341759B1 (es) |
| JP (1) | JP2004513164A (es) |
| AT (1) | ATE329901T1 (es) |
| AU (2) | AU2002234134A1 (es) |
| CA (1) | CA2421594A1 (es) |
| DE (1) | DE60120748T2 (es) |
| ES (1) | ES2265447T3 (es) |
| IL (1) | IL154928A0 (es) |
| WO (2) | WO2002038544A2 (es) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60231608D1 (de) * | 2001-04-19 | 2009-04-30 | Eisai R&D Man Co Ltd | Cyclische amidinderivate |
| EP1444224B1 (en) * | 2001-08-14 | 2006-05-03 | Eli Lilly And Company | 3-substituted oxindole beta-3 agonists |
| ATE340794T1 (de) | 2001-08-14 | 2006-10-15 | Lilly Co Eli | Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| AU2002353844A1 (en) | 2001-11-20 | 2003-06-10 | Eli Lilly And Company | Beta 3 adrenergic agonists |
| US7205407B2 (en) | 2001-11-20 | 2007-04-17 | Eli Lilly And Company | 3-Substituted oxindole β3 agonists |
| EP1467733A1 (en) | 2002-01-11 | 2004-10-20 | Eli Lilly And Company | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| DE60321207D1 (en) | 2002-09-19 | 2008-07-03 | Lilly Co Eli | Diaryläther als opioid-rezeptor antagonisten |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| CN1894240A (zh) * | 2003-12-22 | 2007-01-10 | 伊莱利利公司 | 阿片受体拮抗剂 |
| TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| JP2008507532A (ja) | 2004-07-21 | 2008-03-13 | セラヴァンス， インコーポレーテッド | ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト |
| WO2006031556A2 (en) * | 2004-09-10 | 2006-03-23 | Theravance. Inc. | Amidine substituted aryl aniline compounds |
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| AR056968A1 (es) | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | Compuestos espiro-oxindol y composiciones farmacéuticas |
| WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| WO2008046083A2 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
| MX2009003876A (es) | 2006-10-12 | 2009-05-11 | Xenon Pharmaceuticals Inc | Uso de compuestos de espiro-oxindol como agentes terapeuticos. |
| EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| CA3089569C (en) | 2007-06-04 | 2023-12-05 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| KR101286323B1 (ko) | 2008-10-17 | 2013-07-15 | 제논 파마슈티칼스 인크. | 스피로-옥스인돌 화합물 및 치료제로서의 그의 용도 |
| CA2741024A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| EP2470552B1 (en) | 2009-08-26 | 2013-11-13 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| MY165579A (en) | 2009-10-14 | 2018-04-05 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| CN105726531A (zh) | 2010-02-26 | 2016-07-06 | 泽农医药公司 | 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| MX2015001500A (es) | 2012-08-02 | 2015-04-08 | Merck Sharp & Dohme | Compuestos antidiabeticos triciclicos. |
| BR112015006230A2 (pt) * | 2012-10-02 | 2017-07-04 | Lilly Co Eli | métodos para aprimorar produção de galinha |
| AU2014219020A1 (en) | 2013-02-22 | 2015-07-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
| EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| RS65632B1 (sr) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Ltd | Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe |
| WO2014202580A1 (en) * | 2013-06-20 | 2014-12-24 | Boehringer Ingelheim International Gmbh | Spiro-substituted oxindole derivatives having ampk activity |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
| US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| CN114981518A (zh) | 2020-02-05 | 2022-08-30 | 贝克休斯油田作业有限责任公司 | 利用球形切口的切割器几何形状 |
| US11719050B2 (en) | 2021-06-16 | 2023-08-08 | Baker Hughes Oilfield Operations Llc | Cutting elements for earth-boring tools and related earth-boring tools and methods |
| US11920409B2 (en) | 2022-07-05 | 2024-03-05 | Baker Hughes Oilfield Operations Llc | Cutting elements, earth-boring tools including the cutting elements, and methods of forming the earth-boring tools |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH624395A5 (es) | 1976-01-08 | 1981-07-31 | Ciba Geigy Ag | |
| CA1116598A (en) | 1977-07-13 | 1982-01-19 | William T. Comer | 3-indolyl-tertiary butylaminopropanols |
| JPS6010021B2 (ja) * | 1979-01-31 | 1985-03-14 | 田辺製薬株式会社 | 新規ベンジルアルコ−ル誘導体及びその製法 |
| DE3310891A1 (de) * | 1983-03-25 | 1984-09-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
| DE3423429A1 (de) | 1984-06-26 | 1986-01-02 | Beiersdorf Ag, 2000 Hamburg | Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen |
| DE3426419A1 (de) | 1984-07-18 | 1986-01-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
| US4728651A (en) | 1985-10-24 | 1988-03-01 | Hoechst-Roussel Pharmaceuticals Inc. | Antihypertensive thieno-isoxazoles and -pyrazoles |
| GB8528633D0 (en) | 1985-11-21 | 1985-12-24 | Beecham Group Plc | Compounds |
| US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| CA2145257A1 (en) | 1994-03-23 | 1995-09-24 | Takashi Fujita | Thiazolidine and oxazolidine derivatives, their preparation and their medical use |
| US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
| ZA967892B (en) * | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| EP0906310A4 (en) | 1996-06-07 | 1999-09-01 | Merck & Co Inc | OXADIAZOLE-BENZOSULFONAMIDES AS SELECTIVE BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETIS AND OBESITY |
| US5808080A (en) * | 1996-09-05 | 1998-09-15 | Eli Lilly And Company | Selective β3 adrenergic agonists |
| ES2171839T3 (es) | 1996-09-05 | 2002-09-16 | Lilly Co Eli | Analogos de carbazol como agonistas adrenergicos selectivos de beta3. |
| EP0968209A1 (en) | 1997-01-28 | 2000-01-05 | Merck & Co., Inc. | THIAZOLE BENZENESULFONAMIDES AS $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
| US6011048A (en) * | 1997-01-28 | 2000-01-04 | Merck & Co., Inc. | Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity |
| AUPP796798A0 (en) | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| JP2003055344A (ja) | 1999-01-29 | 2003-02-26 | Dainippon Pharmaceut Co Ltd | ３，７−ジ置換インドール誘導体及びそれを含有する医薬組成物 |
| WO2001007026A2 (en) | 1999-07-22 | 2001-02-01 | Eli Lilly And Company | Improved method of treating type ii diabetes and obesity |
| WO2001035947A2 (en) | 1999-11-15 | 2001-05-25 | Eli Lilly And Company | Treating wasting syndromes with aryloxy propanolamines |
| AU1580001A (en) | 1999-11-15 | 2001-05-30 | Eli Lilly And Company | Process for the preparation of aryloxy propanolamines |
| US6420365B1 (en) | 2000-01-18 | 2002-07-16 | Neurogen Corporation | Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors |
-
2001
- 2001-10-26 EP EP01985160A patent/EP1341759B1/en not_active Expired - Lifetime
- 2001-10-26 AU AU2002234134A patent/AU2002234134A1/en not_active Abandoned
- 2001-10-26 JP JP2002541080A patent/JP2004513164A/ja active Pending
- 2001-10-26 WO PCT/US2001/050666 patent/WO2002038544A2/en active IP Right Grant
- 2001-10-26 ES ES01985160T patent/ES2265447T3/es not_active Expired - Lifetime
- 2001-10-26 US US10/399,206 patent/US6825220B2/en not_active Expired - Fee Related
- 2001-10-26 DE DE60120748T patent/DE60120748T2/de not_active Expired - Fee Related
- 2001-10-26 AT AT01985160T patent/ATE329901T1/de not_active IP Right Cessation
- 2001-10-26 IL IL15492801A patent/IL154928A0/xx unknown
- 2001-10-26 CA CA002421594A patent/CA2421594A1/en not_active Abandoned
- 2001-11-02 WO PCT/US2001/027793 patent/WO2002038543A2/en not_active Application Discontinuation
- 2001-11-02 AU AU2432002A patent/AU2432002A/xx active Pending
-
2004
- 2004-10-21 US US10/970,194 patent/US7122680B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE329901T1 (de) | 2006-07-15 |
| AU2432002A (en) | 2002-05-21 |
| WO2002038544A2 (en) | 2002-05-16 |
| EP1341759A2 (en) | 2003-09-10 |
| US20050054713A1 (en) | 2005-03-10 |
| WO2002038543A3 (en) | 2002-07-04 |
| EP1341759B1 (en) | 2006-06-14 |
| JP2004513164A (ja) | 2004-04-30 |
| CA2421594A1 (en) | 2002-05-16 |
| US6825220B2 (en) | 2004-11-30 |
| US7122680B2 (en) | 2006-10-17 |
| ES2265447T3 (es) | 2007-02-16 |
| WO2002038544A3 (en) | 2002-09-26 |
| DE60120748D1 (de) | 2006-07-27 |
| AU2002234134A1 (en) | 2002-05-21 |
| US20040097532A1 (en) | 2004-05-20 |
| DE60120748T2 (de) | 2007-05-16 |
| WO2002038543A2 (en) | 2002-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2432002A (en) | 3-substituted oxindole beta 3 agonists | |
| ATE297925T1 (de) | 3-substituierte oxindol beta 3 agonisten | |
| AU2002318206A1 (en) | 3-substituted oxindole beta-3 agonists | |
| DK0687251T3 (da) | 1,3-dihydroindol-2-on-derivater, der er substitueret i 3-stillingen med en nitrogengruppe, til anvendelse som vasopressin- og/eller ocytocin-agonister og/eller -antagonister | |
| IL180603A (en) | 3,4-Dihydro-1 H- Naphthalanones which are glucocorticoid receptor modulators | |
| ATE390922T1 (de) | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten | |
| WO2004048345A3 (en) | 2,5-diketopiperazines for the treatment of obesity | |
| PL311204A1 (en) | Indole derivatives as antagonists of 5-ht-like receptors for use in hemicrania | |
| CZ305838B6 (cs) | N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6 | |
| MXPA04004457A (es) | Novedosos derivados de 1,2,4-tiadiazolio como moduladores del receptor de melanocortina. | |
| MY117251A (en) | Use of central cannabinoid receptor antagonists for the preparation of drugs | |
| MX2007008614A (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r). | |
| ATE340794T1 (de) | Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes | |
| DK0760811T3 (da) | Imidazolderivater som histaminreceptor H3-modulatorer | |
| AU4831899A (en) | 5-HT1F agonists | |
| MXPA03000450A (es) | Sulfonamidas de ciclilamina como agonistas del receptor adrenergico beta-3. | |
| KR970704438A (ko) | 티아졸 및 티아디아졸 화합물의 D 도파민 수용체 리간드로서의 용도(Use of Thiazole and Thiadiazole Compounds as D Dopamine Receptor Ligands) | |
| DE602004024383D1 (de) | Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists | |
| TWI265926B (en) | Polymorphic hemisulphate salt of the compound 3-(N-methyl-2-(R)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethyl)-1H-indole | |
| EP1084711A4 (en) | REMEDIES, CONTAINING PGD 2 ANTAGONISTS | |
| IL125960A0 (en) | Novel sulphur derivatives comprising an amide bond method for preparing same use thereof as drugs and pharmaceutical compositions containing such derivatives | |
| EP0908452A3 (en) | Process for preparing 3-substituted indazoles | |
| IL145645A0 (en) | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists | |
| SE9702002D0 (sv) | Novel compounds | |
| PT1282617E (pt) | Derivados de hidantoína com afinidade para os receptores da somatostatina |